Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin

Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet